The Senate has approved a pro-transparency amendment sponsored by Senator Patrick Leahy (D-VT) to the Food and Drug Administration Safety and Innovation Act. Senator Leahy's amendment will preserve public access to information in the agency's possession related to drugs and pharmaceuticals. The Act originally would have allowed the agency to deny public access to information relating to drugs obtained from a federal, state, local, or foreign government agency if that agency had requested that the information be kept confidential. Many members of the government transparency and accountability community objected in a letter to Congress, highlighting the importance of transparency regarding drug information and the potential health and safety risks created by the original language. For more information, see Openthegovernment.org and EPIC: Open Government.
Share this page:
EPIC relies on support from individual donors to pursue our work.
Subscribe to the EPIC Alert
The EPIC Alert is a by-monthly newsletter highlighting emerging privacy issues.